Pharming Technologies

Company snapshot

Pharming Technologies is a pharma organization headquartered in Leiden, NL. Primary therapeutic focus areas include Activated Phosphoinositide 3-Kinase Delta Syndrome, primary immunodeficiency, Common variable immunodeficiency. NovaPharmaNews links 8 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (3), phase 2 (3), phase 3 (2).

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Pharming Technologies. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Pharming Technologies.

1. Jun 8, 2026 Clinical update

   LE 6101 — Phase 1

2. Jun 8, 2026 Clinical update

   LE 5101 — Phase 1

3. Jun 8, 2026 Clinical update

   LE 1102 — Phase 1

4. Jun 8, 2026 Clinical update

   LE 8201 — Phase 2

5. Jun 8, 2026 Clinical update

   LE 7X01 — Phase 2

View all clinical trial activity →

• What is Pharming Technologies?

  Pharming Technologies is a pharma organization headquartered in Leiden, NL. Primary therapeutic focus areas include Activated Phosphoinositide 3-Kinase Delta Syndrome, primary immunodeficiency, Common variable immunodeficiency. NovaPharmaNews links 8 clinical program(s), 0 drug p

• Is Pharming Technologies publicly traded?

  Pharming Technologies appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Pharming Technologies develop or market?

  We link 11 drug profile(s) where Pharming Technologies is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pharming-technologies-b-v#company-drugs.

• What are the latest developments for Pharming Technologies?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Pharming Technologies focus on?

  Pharming Technologies focuses on Activated Phosphoinositide 3-Kinase Delta Syndrome, primary immunodeficiency, Common variable immunodeficiency based on our analysis of their pipeline programs and drug development activities.